The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Sulfamates and their therapeutic potential
Abstract
Starting from the very simple molecule sulfamic acid, O‐substituted‐, N‐substituted‐, or di‐/tri‐substituted sulfamates may be obtained, which show specific biological activities which were or started to be exploited for the design of many types of therapeutic agents. Among them, sulfamate inhibitors of aminoacyl‐tRNA synthetases (aaRSs) were recently reported, constituting completely new classes of antibiotics, useful in the fight of drug‐resistant infections. Anti‐viral agents incorporating sulfamate moieties have also been obtained, with at least two types of such derivatives investigated: the nucleoside/nucleotide human immunodeficiency virus (HIV) reverse transcriptase inhibitors, and the HIV protease inhibitors (PIs). In the increasing armamentarium of anti‐cancer drugs, the sulfamates occupy a special position, with at least two important targets evidenced so far: the steroid sulfatases (STSs) and the carbonic anhydrases (CAs). An impressing number of inhibitors of STSs of the sulfamate type have been reported in the last years, with several compounds, such as 667COUMATE among others, progressing to clinical trials for the treatment of hormone‐dependent tumors (breast and prostate cancers). This field is rapidly evolving, with many types of new inhibitors being constantly reported and designed in such a way as to increase their anti‐tumor properties, and decrease undesired features (for example, estrogenicity, a problem encountered with the first generation such inhibitors, such as EMATE). Among the many isozymes of CAs, at least two, CA IX and CA XII, are highly overexpressed in tumors, being generally absent in the normal tissues. Inhibition of tumor‐associated CAs was hypothesized to lead to novel therapeutic approaches for the treatment of cancer. Many sulfamates act as very potent (low nanomolar) CA inhibitors. The X‐ray crystal structure of the best‐studied isozyme, CA II, with three sulfamates (sulfamic acid, topiramate, and EMATE) has recently been reported, which allowed for a rationale drug design of new inhibitors. Indeed, low nanomolar CA IX inhibitors of the sulfamate type have been reported, although such compounds also act as efficient inhibitors of isozymes CA I and II, which are not associated with tumors. A large number of anti‐convulsant sulfamates have been described, with one such compound, topiramate, being widely used clinically as anti‐epileptic drug. By taking into consideration a side effect of topiramate, an anti‐epileptic drug leading to weight loss in some patients, it has recently been proposed to use this drug and related sulfamates for the treatment of obesity. The rationale of this use is based on the inhibition of the mitochondrial CA isozyme, CA V, involved in lipogenesis. Some sulfamates were also shown to possess potent inhibitory activity against acyl coenzyme A:cholesterol acyltransferase, an enzyme involved in cholesterol metabolism. One such agent, avasimibe, is in advanced clinical trials for the treatment of hyperlipidemia and atherosclerosis. Thus, the sulfamate moiety offers very attractive possibilities for the drug design of various pharmacological agents, which are on one hand due to the relative ease with which such compounds are synthesized, and on the other one, due to the fact that biological activity of most of them is impressive. © 2004 Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Topiramate-Induced Nephrolithiasis
Kuo, R. L., Moran, M. E., Kim, D. H., Abrahams, H. M., White, M. D., & Lingeman, J. E. (2002) · Journal of Endourology · doi:10.1089/089277902753752188 · Cited by 76
Cited by
Yu, W., He, X., Vanommeslaeghe, K., & MacKerell, A. D. (2012) · Journal of Computational Chemistry · doi:10.1002/jcc.23067 · Cited by 922
McElroy, S. L., Hudson, J. I., Capece, J. A., Beyers, K., Fisher, A. C., & Rosenthal, N. R. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.08.008 · Cited by 281
Medicinal significance of benzothiazole scaffold: an insight view
Sharma, P. C., Sinhmar, A., Sharma, A., Rajak, H., & Pathak, D. P. (2013) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.3109/14756366.2012.720572 · Cited by 256
Bays, H. (2010) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.10.125 · Cited by 66
Metadata
- Authors
- Winum, J., Scozzafava, A., Montero, J., & Supuran, C. T.
- Venue
- Medicinal Research Reviews
- Publisher
- Wiley
- Published
- 2004-10-11
- Volume
- 25
- Issue
- 2
- Pages
- 186-228
- ISSN
- 0198-6325 (ISSN-L)
- 1098-1128
- OpenAlex
- W2100386666
- Cited by
- 206
- References
- 1
- FWCI
- 4.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sulfamates and their therapeutic potential. https://app.cochat.ai/papers/10.1002/med.20021
- The paper
- Winum, J., Scozzafava, A., Montero, J., & Supuran, C. T. (2005). Sulfamates and their therapeutic potential. Medicinal Research Reviews. https://doi.org/10.1002/med.20021
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.